Comparison of the cryoprotective solutions based on human albumin vs. autologous plasma: its effect on cell recovery, clonogenic potential of peripheral blood hematopoietic progenitor cells and engraftment after autologous transplantation

Vox Sanguinis
A SmagurS Giebel

Abstract

Cryopreservation of peripheral blood hematopoietic progenitor/stem cells (PBPCs) requires the addition of cryoprotectant such as DMSO, often prediluted using human serum albumin solution (HSAS). The goal of our study was to verify whether the HSAS may be replaced by autologous plasma (AP) without negative impact on PBPCs quality and engraftment. AP usage is less expensive and allows performing cell preparation in a 'closed system', and hence to reduce the risk of product contamination. Peripheral blood progenitor cells from 18 patients were divided into two aliquots (500 μl) placed in separate vials, each containing 7·5% DMSO prediluted with 5% HSAS or AP. Post-thaw cell recovery and clonogenic potential was evaluated. During clinical part of the study, the impact of both cryoprotective solution on hematopoietic engraftment was evaluated in two cohorts (n = 26) matched for diagnosis, age and the number of transplanted CD34+ cells. The median recovery of nucleated cells and the number of colony-forming units did not differ between tested cryoprotective mixtures. For AP mixture, neither total protein nor albumin concentration of plasma correlated with cell recovery and clonogenic potential of the PBPCs after cryopreservation. In ...Continue Reading

References

Nov 1, 1996·Bone Marrow Transplantation·E Gluckman
Jul 15, 2003·Journal of Hematotherapy & Stem Cell Research·A M BakkenJ F Abrahamsen
Jul 27, 2005·Bone Marrow Transplantation·P WindrumUNKNOWN EBMT Chronic Leukaemia Working Party Complications Subcommittee
Feb 3, 2007·American Journal of Hematology·David BerzPeter J Quesenberry
Apr 14, 2007·Transfusion Medicine·D SkoricP Rodic
Jan 29, 2008·Current Stem Cell Research & Therapy·Anne Margrethe Bakken
Nov 11, 2008·Bone Marrow Transplantation·J JansenJ M Thompson
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hillard M LazarusMary Eapen
Jul 9, 2009·Bone Marrow Transplantation·P LjungmanUNKNOWN European Group for Blood and Marrow Transplantation
Apr 29, 2010·JAMA : the Journal of the American Medical Association·Alois GratwohlUNKNOWN Worldwide Network of Blood and Marrow Transplantation
Mar 2, 2011·Bone Marrow Transplantation·H BaldomeroUNKNOWN European Group for Blood and Marrow Transplantation EBMT
Aug 21, 2012·Cytotherapy·Gregory S VosganianJames R Mason
Apr 16, 2013·Bone Marrow Transplantation·J R PasswegUNKNOWN European Group for Blood and Marrow Transplantation
Apr 30, 2013·Transfusion·Jolanta Antoniewicz-PapisMagdalena Łętowska
Nov 15, 2013·Transfusion·Martin G GuttridgeSuzanne M Watt

❮ Previous
Next ❯

Citations

May 24, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Lucilla LecchiMaurizio Marconi
Jul 21, 2020·Cryobiology·Shahensha ShaikRam Devireddy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.